tbuckley/cabot-search huggingface dataset:
Ambient air pollution, traffic noise and adult asthma prevalence: a BioSHaRE approach
Authors: Yutong Cai, Wilma L. Zijlema, Dany Doiron, Marta Blangiardo, Paul R. Burton, Isabel Fortier, Amadou Gaye, John Gulliver, Kees de Hoogh, Kristian Hveem, Stéphane Mbatchou, David W. Morley, Ronald P. Stolk, Paul Elliott, Anna L. Hansell, Susan Hodgson
Journal: European Respiratory Journal (2016)

We investigated the effects of both ambient air pollution and traffic noise on adult asthma prevalence, using harmonised data from three European cohort studies established in 2006–2013 (HUNT3, Lifelines and UK Biobank). Residential exposures to ambient air pollution (particulate matter with aerodynamic diameter ≤10 µm (PM 10 ) and nitrogen dioxide (NO 2 )) were estimated by a pan-European Land Use Regression model for 2007. Traffic noise for 2009 was modelled at home addresses by adapting a standardised noise assessment framework (CNOSSOS-EU). A cross-sectional analysis of 646 731 participants aged ≥20 years was undertaken using DataSHIELD to pool data for individual-level analysis via a “compute to the data” approach. Multivariate logistic regression models were fitted to assess the effects of each exposure on lifetime and current asthma prevalence. PM 10 or NO 2 higher by 10 µg·m −3 was associated with 12.8% (95% CI 9.5–16.3%) and 1.9% (95% CI 1.1–2.8%) higher lifetime asthma prevalence, respectively, independent of confounders. Effects were larger in those aged ≥50 years, ever-smokers and less educated. Noise exposure was not significantly associated with asthma prevalence. This study suggests that long-term ambient PM 10 exposure is associated with asthma prevalence in western European adults. Traffic noise is not associated with asthma prevalence, but its potential to impact on asthma exacerbations needs further investigation.
Rapid Immune Reconstitution after a Reduced-Intensity Conditioning Regimen and a CD3-Depleted Haploidentical Stem Cell Graft for Pediatric Refractory Hematologic Malignancies.
Authors: Xiaohua Chen, Gregory A. Hale, Raymond C. Barfield, Ely Benaim, Wing H. Leung, James Knowles, Edwin M. Horwitz, Paul Woodard, Kimberly A. Kasow, Usman Yusuf, Fred G. Behm, Randall T. Hayden, Sheila A. Shurtleff, Victoria Turner, Deo Kumar Srivastava, Rupert Handgretinger
Journal: Blood (2006)
Neovasculature and circulating tumor cells dual-targeting nanoparticles for the treatment of the highly-invasive breast cancer
Authors: Jianhui Yao, Jingxian Feng, Xiaoling Gao, Dan Wei, Ting Kang, Qianqian Zhu, Tianze Jiang, Xunbin Wei, Jun Chen
Journal: Biomaterials (2016)
Single Nucleotide Polymorphisms Within The Thrombomodulin Gene (THBD) Predict Risk Of Non-Relapse Mortality In Patients With Graft-Versus-Host Disease
Authors: Thomas Luft, Olaf Penack, Olga Blau, Sascha Dietrich, Berend H. Isermann, Anthony D Ho, Lutz Uharek, Peter Dreger, Rajive Kumar, Krishna P.S. Rachakonda
Journal: Blood (2013)
Erlotinib (E) as adjuvant treatment for patients (pts) with resected head and neck squamous cell carcinoma (HNSCC) with evaluation of neoadjuvant biomarker modulation with E with or without sulindac (S): a feasibility report
Authors: J. R. Grandis, S. Y. Lai, F. R. Esteve, S. W. Kim, R. L. Ferris, M. K. Gibson, R. Johnson, D. E. Heron, J. T. Johnson, A. E. Argiris
Journal: Journal of Clinical Oncology (2008)

6037 Background: Epidermal growth factor receptor (EGFR) and G-protein-coupled receptor (GPCR) ligands, such as prostaglandin E2, are upregulated in HNSCC; cross-talk occurs between EGFR and GPCR signaling. E, an EGFR tyrosine kinase inhibitor, plus S, a cyclooxygenase 1/2 inhibitor, are synergistic in killing HNSCC cells (Thomas et al. Cancer Research 2006). We sought to identify tumor biomarkers that are modulated by E with or without S and to assess the efficacy of adjuvant E in resected HNSCC. Methods: Pts with resectable HNSCC, clinical stage II-IVA, of the oral cavity, oropharynx, hypopharynx or larynx are randomly assigned to receive E 150 mg orally QD plus S 150 mg orally BID (Arm A), E 150 mg QD (Arm B), or placebo QD (Arm C) for 7–14 days, continued until the day prior to surgery, in a 5:5:3 ratio. 4–6 weeks after completing platinum-based postoperative chemoradiotherapy (CRT), pts receive adjuvant E 150 mg QD for 2 years. The primary endpoint is the 3-year disease-free survival and the sample size 85 pts assuming a drop-out rate of 10%. Results: 30 pts were accrued between 12/5–10/07. Primary site: oral cavity, 24; larynx, 3; hypopharynx, 2; oropharynx, 1. Median age 61 years (33–82). 29 pts received a median of 7 days of neoadjuvant therapy (7–14); 1 pt withdrew consent. Adverse events during neoadjuvant portion (arms remain blinded): grade (G)1 rash (4), G1 nausea (1) and G1 stomatitis (1). 28 pts had surgery as planned (1 pt progressed and deemed unresectable). Pathologic stage: I, 3; II, 3; III, 6; IV, 16. Median time of hospitalization was 9 days. Postoperative complications included fistula (2), wound infection (2) and bleeding (1). Of 20 pts who completed postop RT, 5 (20%) received adjuvant E; 15 pts did not initiate adjuvant E due to transportation issues (4), refusal (4), stage I (3) recurrence (1), others (3). Of 5 pts who started E, 3 discontinued E in 2–4 months; 2 due to G1/2 toxicities (rash, diarrhea, fatigue) and 1 due to recurrence. Conclusions: Preliminary results show that the neoadjuvant biomarker study is safe and feasible. However, there are significant drop-out rates and low compliance with adjuvant E. Results of biomarker studies are pending. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration OSI Oncology
GW26-e4398 Cardioprotection of PI3K-mediated signaling is required for anti-arrhythmia effects and myocardial repair of ischemic preconditioning in infarcted pig hearts
Authors: Lan Zhao, Feng Su, Jiahong Wang, Nannan Chen, Qunlin Gong, Jinhui Tang, Hao Wang, Jianhua Yao, Qin Wang, Jian Yan, Shaoheng Zhang
Journal: Journal of the American College of Cardiology (2015)
Effectiveness of concurrent radiation therapy combined with peroral chemotherapy (UFT or TS-1 ) for T2N0 glottic cancer in Japanese population
Authors: Y. Niibe, K. Hayakawa, M. Nakayama, T. Matsubayashi, H. Takahashi, M. Okamoto
Journal: Journal of Clinical Oncology (2007)

16538 Background: The current study retrospectively reviewed 147 T2N0 glottic cancer patients treated at Kitasato University Hospital to compare concurrent radiation therapy combined with chemotherapy (most of them: UFT or TS-1, peroral anti-cancer drugs), with conventional radiation therapy. Methods: One-hundred and forty-seven patients with T2N0 glottic cancer treated with radiation therapy alone or radiation therapy combined with peroral (UFT or TS-1)or intravenous chemotherapy between 1974 and 2005 at Kitasato University Hospital. The median age of all patients was 64 years (range; 45–86 years). As for gender, 145 were males and the others were females. As for radiation therapy protocol, all except one were treated with 2 Gy per fraction, 5 fractions per week and a total of 60 Gy. Only one patient was treated with 1.8 Gy per fraction, 5 fractions per week and a total of 61.2 Gy. As for chemotherapy protocol, 83 patients were concurrently given UFT, (UFT group). 24 patients given TS-1, (TS-1 group) and 23 patients underwent intravenous chemotherapy using mainly cisplatin (Pt. group). The other 23 patients underwent no chemotherapy. Results: The median follow-up time was 61 months (range; 3–372 months). The 5-year local control rates of all patients was 83.4 %. Stratified by radiation therapy alone group (RT group) and concurrent chemoradiation therapy (CCRT group), The 5-year local control rates of RT group and CCRT group were 82.7%, 83.4%, respectively (p=NS). Stratified by chemotherapy regimens of CCRT group, 3-year local control rates of UFT group, TS-1 group and Pt. group were 90.1%, 100.0% and 73.4%, respectively, which indicated the peroral chemotherapy was not inferior to intravenous chemotherapy. As for morbidity, 2 patients of UFT group experienced severe enteritis . Conclusion: Concurrent radiation therapy combined with UFT or TS-1 for T2N0 glottic cancer might be the one of standard treatments in Japanese Population. Furthermore, concurrent use of TS-1 might perform break-through for T2N0 glottic cancer in terms of local control rate, overall survival and burdens of treatment on patients. No significant financial relationships to disclose.
Pegfilgrastim Accelerates Neutrophil Engraftment, Reduces the Number of Neutropenic and Hospitalization Days and the Use of Antibiotics After Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma and Lymphoma. A Phase II Study and Comparison with a Filgrastim Treated Historical Cohort.
Authors: Luciano Wannesson, François Luthi, Emanuele Zucca, Anne Rosselet, Mauro Baglioni, Erika Lerch, Kristin Feuerlein, Michele Ghielmini, Nicolas Ketterer
Journal: Blood (2009)
Comment on Qian et al. Metabolic Effects of Monounsaturated Fatty Acid–Enriched Diets Compared With Carbohydrate or Polyunsaturated Fatty Acid–Enriched Diets in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2016;39:1448–1457
Authors: Lukas Schwingshackl, Georg Hoffmann
Journal: Diabetes Care (2016)

We read with great interest the meta-analysis by Qian et al. (1). The authors showed consistent evidence that replacing carbohydrates with monounsaturated fatty acids (MUFA) has beneficial effects on metabolic risk factors in patients with type 2 diabetes (T2D) and concluded that these findings have broad implications for dietary recommendations for this population.

Recently, we summarized the evidence from systematic reviews and meta-analyses regarding the effects of MUFA on cardiometabolic risk (2). In patients with abnormal glucose metabolism …
RhoA Is Essential for Maintaining Normal Megakaryocyte Ploidy Distribution and Platelet Generation
Authors: Aae Suzuki, Jae-Won Shin, Yuhuan Wang, Mortimer Poncz, John K. Choi, Dennis E Discher, Christopher L. Carpenter, Lurong Lian, Liang Zhao, Yanfeng Wang, Charles S. Abrams
Journal: Blood (2012)
GW26-e2938 Research on pharmacological mechanisms of Qishen Granule using Methodology 1H-NMR Metabolomics in mini pigs with cardiac functional insufficiency and qi-deficiency and blood stasis syndrome(QDBS) induced by Ameroid constricting ring
Authors: Wenjing Chuo, Shuzhen Guo, Zhongfeng Li, Qi Qiu, Hongjian Lian, Yong Wang, Bangze Fu, Chun Li, Yang Lin, Wei Wang
Journal: Journal of the American College of Cardiology (2015)
Outcome of Early T-Cell Precursor Acute Lymphoblastic Leukemia in AIEOP Patients Treated with the AIEOP-BFM ALL 2000 Study
Authors: Valentino Conter, Maria Grazia Valsecchi, Barbara Buldini, Rosanna Parasole, Franco Locatelli, Antonella Colombini, Maurizio Arico', Carmelo Rizzari, Maria Caterina Putti, Elena Barisone, Luca Lo Nigro, Nicola Santoro, Ottavio Ziino, Andrea Pession, Anna Maria Testi, Concetta Micalizzi, Fiorina Casale, Daniela Silvestri, Giovanni Cazzaniga, Andrea Biondi, Giuseppe Basso
Journal: Blood (2014)
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
Authors: Alex F. Herrera, Matthew Mei, Lawrence Low, Haesook T. Kim, Gabriel K. Griffin, Joo Y. Song, Reid W. Merryman, Victoria Bedell, Christine Pak, Heather Sun, Tanya Paris, Tracey Stiller, Jennifer R. Brown, Lihua E. Budde, Wing C. Chan, Robert Chen, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, Joyce Murata-Collins, Auayporn P. Nademanee, Joycelynne M. Palmer, German A. Pihan, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Aliyah R. Sohani, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, David M. Weinstock, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Scott J. Rodig, Amrita Krishnan, Philippe Armand
Journal: Journal of Clinical Oncology (2016)

Purpose Double-hit lymphomas (DHLs) and double-expressor lymphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with poor outcomes after standard chemoimmunotherapy. Data are limited regarding outcomes of patients with relapsed or refractory (rel/ref) DEL or DHL who undergo autologous stem-cell transplantation (ASCT). We retrospectively studied the prognostic impact of DEL and DHL status on ASCT outcomes in patients with rel/ref DLBCL. Methods Patients with chemotherapy-sensitive rel/ref DLBCL who underwent ASCT at two institutions and in whom archival tumor material was available were enrolled. Immunohistochemistry for MYC, BCL2, and BCL6 and fluorescence in situ hybridization (FISH) for MYC were performed. In cases with MYC rearrangement or copy gain, FISH for BCL2 and BCL6 was also performed. Results A total of 117 patients were included; 44% had DEL and 10% had DHL. DEL and DHL were associated with inferior progression-free survival (PFS), and DHL was associated with poorer overall survival (OS). The 4-year PFS in patients with DEL compared with those with non-DEL was 48% versus 59% ( P = .049), and the 4-year OS was 56% versus 67% ( P = .10); 4-year PFS in patients with DHL compared with those with non-DHL was 28% versus 57% ( P = .013), and 4-year OS was 25% versus 61% ( P = .002). The few patients with concurrent DEL and DHL had a poor outcome (4-year PFS, 0%). In multivariable models, DEL and DHL were independently associated with inferior PFS, whereas DHL and partial response ( v complete response) at transplant were associated with inferior OS. Conclusion DEL and DHL are both associated with inferior outcomes after ASCT in patients with rel/ref DLBCL. Although ASCT remains a potentially curative approach, these patients, particularly those with DHL, are a high-risk subset who should be targeted for investigational strategies other than standard ASCT.
Population Based Genotyping of Human Leukocyte Antigen (HLA) in Hodgkin Lymphoma: EBV Positive HL Is Associated with HLA Class I and EBV Negative HL Is Associated with HLA Class III.
Authors: Arjan Diepstra, Marijke Niens, Edo Vellenga, Gerard J. te Meerman, Michael Schaapveld, Ilja M. Nolte, Gustaaf W. van Imhoff, Sibrand Poppema
Journal: Blood (2004)
PAX5/TEL Exhibits a Dominant-Negative Role by Inhibiting the Expression of Genes Involved in BCR Signalling and Suppressing the Binding of Wild Type PAX5 to Its Direct Target Gene CD79A (mb-1) in a human Pre-B ALL Cell Line.
Authors: Gabriela B. Iwanski, Nils Heinrich Thoennissen, PohYeen Lor, Norihiko Kawamata, Daniel Nowak, Grazia Fazio, Andrea Biondi, Giovanni Gazzaniga, H. Phillip Koeffler
Journal: Blood (2009)
A Precision Medicine Approach to Clinical Trials
Authors: Rita Rubin
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Imipenem heteroresistance in nontypeable Haemophilus influenzae is linked to a combination of altered PBP3, slow drug influx and direct efflux regulation
Authors: A. Cherkaoui, S.M. Diene, A. Renzoni, S. Emonet, G. Renzi, P. François, J. Schrenzel
Journal: Clinical Microbiology and Infection (2016)
Comment on Ferrannini et al. Diabetes Care 2016;39:1108–1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115–1122
Authors: Antonio Ceriello, Stefano Genovese, Edoardo Mannucci, Edoardo Gronda
Journal: Diabetes Care (2016)

In their recent articles, Ferrannini et al. (1) and Mudaliar et al. (2) suggest that increased ketonemia, improving heart function, might explain the positive results of the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study. This suggestion perfectly fits with our recently published hypothesis that glucagon could be the key player of the observed results of EMPA-REG OUTCOME (3). Empagliflozin increases …
A Multi-Center Analysis of Renal Impairment as a Potential Prognostic Factor: Analysis in Multiple Myeloma Patients Treated with Standard or High-Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Martina Kleber, Gabriele Ihorst, Christian Jakob, Peter Liebisch, Bernd Koch, Monika Engelhardt
Journal: Blood (2007)
Low Density Granulocytes in Patients after Allogeneic Hematopoietic Stem Cells Transplantation (allo-HSCT): A Distinct Class of Neutrophils in Systemic Alloimmunity
Authors: Ekaterina Mikhaltsova, Valeri G. Savchenko, Larisa A. Kuzmina, Mikhail Drokov, Vera Vasilyeva, Olga Koroleva, Daria Dubnyak, Elena N. Parovichnikova
Journal: Blood (2015)
Use of Dexamethasone Given to Sibling Donors as a Way of In Vivo Purging of Allo Reactive Donor T Cells in rhg-CSF Mobilized Peripheral Blood Stem Cell Transplantations Resulted in Significant Decrease in CD3+ Cells and Increased CD34+ Yield.
Authors: Khaleel K. Ashraf, Arabella B. Tilden, Yufeng Li, Lawrence Lamb, Donna E. Salzman, Matthew H. Carabasi, Richard Lopez, William P. Vaughan
Journal: Blood (2007)
A Positive Feedback Loop of lncRNA-<i>PVT1</i> and FOXM1 Facilitates Gastric Cancer Growth and Invasion
Authors: Mi-die Xu, Yiqin Wang, Weiwei Weng, Ping Wei, Peng Qi, Qiongyan Zhang, Cong Tan, Shu-juan Ni, Lei Dong, Yusi Yang, Wanrun Lin, Qinghua Xu, Dan Huang, Zhaohui Huang, Yuqing Ma, Wei Zhang, Weiqi Sheng, Xiang Du
Journal: Clinical Cancer Research (2016)

Purpose: The long, noncoding RNA (lncRNA) PVT1 is an important epigenetic regulator with a critical role in human tumors. Here, we aimed to investigate the clinical application and the potential molecular mechanisms of PVT1 in gastric cancer tumorigenesis and progression.Experimental Design: The expression level of PVT1 was determined by RT-qPCR analysis in 190 pairs of gastric cancer tissues and adjacent normal gastric mucosa tissues (ANT). The biologic functions of PVT1 were assessed by in vitro and in vivo functional experiments. RNA protein pull-down assays and LS/MS mass spectrometry analysis were performed to detect and identify the PVT1- interacting protein FOXM1. Protein-RNA immunoprecipitation assays were conducted to examine the interaction of FOXM1 and PVT1 Chromatin immunoprecipitation (ChIP) and luciferase analyses were utilized to identify the binding site of FOXM1 on the PVT1 promoter.Results: The lncRNA PVT1 was significantly upregulated in gastric cancer tissues compared with ANTs. High expression of PVT1 predicted poor prognosis in patients with gastric cancer. PVT1 enhanced gastric cancer cell proliferation and invasion in vitro and in vivoPVT1 directly bound FOXM1 protein and increased FOXM1 posttranslationally. Moreover, PVT1 is also a FOXM1-responsive lncRNA, and FOXM1 directly binds to the PVT1 promoter to activate its transcription. Finally, PVT1 fulfilled its oncogenic functions in a FOXM1-mediated manner.Conclusions: Our study suggests that PVT1 promotes tumor progression by interacting with FOXM1. PVT1 may be a valuable prognostic predictor for gastric cancer, and the positive feedback loop of PVT1-FOXM1 could be a therapeutic target in pharmacologic strategies. Clin Cancer Res; 23(8); 2071-80. ©2016 AACR.
Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): Final report
Authors: P. Conte, E. Thomas, M. Martin, J. Klimovsky, J. Tabernero
Journal: Journal of Clinical Oncology (2006)

10505 Background: Ixabepilone is the first epothilone analog in a new class of antineoplastic agents, which optimizes the properties of the naturally occurring epothilone B. The epothilones promote tumor cell death by uniquely binding to tubulin and stabilizing microtubules. Methods: This international, multicenter, open-label Phase II trial was designed to assess the activity of ixabepilone in pts with highly resistant MBC who had progressed following taxane treatment. Eligible pts were aged ≥18 years with MBC (progressed on or within 4 months of taxane therapy [or within 6 months if adjuvant taxane only]). Pts must have received a taxane as their last regimen. Pts were excluded if they had received ≥3 prior chemotherapy regimens for MBC or had ≥Grade 2 neuropathy. Ixabepilone was administered intravenously as a 3-hour infusion at a dose of 40 mg/m 2 every 3 weeks. Results: Of 49 pts (median age 54 years, range 30–81), 86% of pts had received at least two prior chemotherapy regimens. 98% had received prior anthracycline treatment. 73% of pts had progressed within 1 month of their last taxane dose. 84% had visceral metastases. Pts received a median of three cycles (range 1–5) and median cumulative dose of 120 mg/m 2 (range 40–498 mg/m 2 ). The tumor response rate (number of responders [complete and partial response]/number of response-evaluable pts) was 12% (95% CI = 4.7–26.5%). All the responders (n = 6) had partial responses; five of the six had not responded to prior taxane therapy. The responders received a median of 10.5 cycles (range 5–15) and had a median duration of response of 10.4 months (95% CI = 6.3–22.0 months). In 20 pts (41%) stable disease was reported as the best overall outcome. The majority of these pts (16 of 20, 80%) received ≥4 cycles of ixabepilone therapy. The median time to progression was 2.2 months (95% CI = 1.4–3.2 months); the median survival was 7.9 months (95% CI = 6.1–14.5 months). Conclusions: Ixabepilone (40 mg/m 2 as a 3-hour infusion every 3 weeks) demonstrates promising antitumor activity, along with an acceptable safety profile in pts with clearly defined taxane-resistant MBC. [Table: see text]
Expression of High Levels of Human γ-Globin in Adult Mice Carrying a Transgene of the Brazilian Type of Hereditary Persistence of Fetal Hemoglobin.
Authors: Anderson F. Cunha, Ana F. Brugnerotto, Monica B. Melo, Marcus A.F. Corat, Ana P. Gimenes, Luiz A.C. Passos, Emily E. Devlin, David M. Bodine, Sara T.O. Saad, Fernando F. Costa
Journal: Blood (2007)
Late Relapses in Acute Myelogenous Leukemia: Analysis of Characteristics and Outcome.
Authors: Dushyant Verma, Stefan Faderl, Susan O’Brien, Sherry Pierce, Jorge Cortes, Khanh Vu, Emil Freireich, Michael J. Keating, Hagop M. Kantarjian, Farhad Ravandi
Journal: Blood (2008)
Platelet Function and Response to Thrombopoietin Mimetics In Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.
Authors: James B. Bussel, Andrew L Frelinger, William B Mitchell, Mariana P Pinheiro, Marc R Barnard, Michael Lampa, Bethan Psaila, Nayla Boulad, Hannah Tamary, Alan D. Michelson
Journal: Blood (2010)